Translational safety biomarkers

Scientific Federation invites all the participants from all over the world to attend 2nd World Congress on Clinical Research &Biomarkers during September 17-18, 2018 Toronto, Canada  which includes Keynote presentations, Oral talks, Poster presentations and Exhibitions.WCCRB-2018 will also provide the excellent opportunity to meet experts, exchange information, and strengthen the collaboration among Directors, Researchers, Associate Professors, and Scholars from both academia and industry.

Translational research is the research process that investigates and translates nonclinical research results into clinical applications and tests their safety and efficacy in a Phase 1 clinical trial. One characteristic of safety biomarkers is that they are noninvasive and translate between species. Biomarkers may have their greatest value in early efficacy and safety evaluations such as in vitro studies in tissue samples, in vivo studies in animal models, and early-phase clinical trials to establish “Proof of Concept.”

Translational safety biomarkers can predict, detect, and monitor drug-induced toxicity during human trials for testing drugs and are needed to assess whether toxicities observed in laboratory animal studies are relevant to humans at therapeutic doses experimental animals, the biomarker also must be one that is relevant to humans. These “Translational Biomarkers” can be rigorously studied in animals, thereby establishing well-defined relationships between biomarker levels and tissue histopathology. There are many animal models and human cohorts that are useful in studying aging, but important limitations include marked differences among them that make translating animal findings to humans difficult, a number of key limitations that affect longitudinal studies in both humans and animals, and the need to study multimorbidity and complexity for translational research to be generalizable to most older adults. There are generally two categories of translational research: Basic to clinical and Clinical to population; however basic to clinical and clinical to population are often used to represent transitions between to patient-oriented, patient oriented to population-based, and basic to population-based research. In third have five categories, which include Basic biomedical research, Clinical translation, Translation to populations, Translation to practice and Demonstrating efficacy.

Results from Basic Biomedical research and Clinical Translation research have impacted numerous policies related to bringing new diagnostics and therapeutics through clinical trials, while findings from Translation Efficacy and Demonstrating efficacy research have been effective in informing policy, especially regarding the models and financing of health care delivery in various populations.